Recent Quotes (30 days)

You have no recent quotes
chg | %

Solta Medical Inc  

(Public, NASDAQ:SLTM)   Watch this stock  
Find more results for SLTM
- Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week     -
Open     -
Vol. 0.00
Mkt cap     -
P/E 0.00
Div/yield     -
EPS 0.02
Shares 80.74M
Beta     -
Inst. own 55%

Key stats and ratios

Q3 (Sep '13) 2012
Net profit margin 1.92% -26.29%
Operating margin 5.95% -24.75%
EBITD margin - 5.95%
Return on average assets 1.12% -17.31%
Return on average equity 1.91% -32.17%
Employees 371 -
CDP Score - -


25881 Industrial Blvd
HAYWARD, CA 94545-2991
United States - Map
+1-510-7822286 (Phone)
+1-510-7866895 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Solta Medical, Inc. designs, develops, manufactures and markets professional and consumer energy-based medical device systems for aesthetic applications. The Company's systems are cleared by the United States Food and Drug Administration (FDA) for dermatological procedures performed in the physician led, professional assist, and personal care markets. The Company’s portfolio of products includes six brands that are primarily designed for aesthetic applications: The Fraxel re:pair system provides ablative laser skin resurfacing while the non-ablative Fraxel platform and Clear + Brilliant systems provide treatment for skin rejuvenation. The Thermage system provides non-invasive skin tightening and the Liposonix system provides non-invasive body contouring. Isolaz and CLARO provide options to resolve acne. In January 2014, Valeant Pharmaceuticals International Inc 's wholly-owned subsidiary Valeant Pharmaceuticals International acquired Solta Medical Inc.